Cell Component – Talk Bio

Incyte and Genesis Therapeutics Forge $620M AI-Driven Drug Discovery Partnership

2 months ago talkbio0Tagged Artificial Intelligence, Drug Discovery, Gemini of Coiled Bodies, Immunology, Neoplasms, small molecule therapeutics, strategic collaboration

Artificial intelligence, drug discovery, small molecule therapeutics, GEMS platform, oncology, immunology, strategic collaboration

Illumina Announces Layoffs as Incyte Forges AI Partnership for Drug Discovery

2 months ago talkbio0Tagged Aortic Valve Insufficiency, Drug Discovery, FOXD3 gene, Gemini of Coiled Bodies, Illumina, Incyte, Partnership

Illumina, layoffs, Incyte, Genesis Therapeutics, AI partnership, drug discovery, GEMS platform, small molecule therapeutics

Dutch Biotech Citryll Secures €85M Funding from J&J and Novartis for Inflammatory Disease Therapy

5 months ago talkbio0Tagged Citryll, Forbion, Inflammatory Disease Therapy, Johnson & Johnson Innovation, Neutrophil Extracellular Traps, Novartis, Series B, venture fund

Citryll, Inflammatory disease therapy, Neutrophil Extracellular Traps (NETs), Series B funding, Johnson & Johnson Innovation, Novartis Venture Fund, Forbion

Rivus Pharmaceuticals Unveils Promising Phase 2a Results for HU6 in Obesity-Related Heart Failure Patients

7 months ago talkbio0Tagged cardiometabolic diseases, CMAs, fat-selective weight loss, HU6, Mitochondria, obesity-related heart failure, Rivus Pharmaceuticals, uncoupling

HU6, Rivus Pharmaceuticals, obesity-related heart failure, fat-selective weight loss, controlled metabolic accelerators (CMAs), mitochondrial uncoupling, cardiometabolic diseases.